| 摘要 |
PROBLEM TO BE SOLVED: To solve the following problems: to date, dexmedetomidine has been provided as a concentrate that must be diluted prior to administration to a patient; and the requirement of a dilution step in the preparation of the dexmedetomidine formulation is associated with additional costs and inconvenience, as well as the risk of possible contamination or overdose due to human error.SOLUTION: This invention relates to: a ready-to-use liquid pharmaceutical composition for parenteral administration to a subject, comprising dexmedetomidine or a pharmaceutically acceptable salt thereof disposed within a sealed glass container, at a concentration of about 0.005 to about 50 μg/mL; and the use or the like of the dexmedetomidine or the pharmaceutically acceptable salt thereof, for the production of the liquid pharmaceutical composition. |
